Pneumococcal vaccine for people over 65
In a trial of 84,500 elderly individuals, the 13-valent pneumococcal vaccine blocked approximately 46% of the types of pneumonia that the vaccine is capable of controlling. It blocked 75% of the most dangerous invasive infections. However, no effect was observed for 'pneumonia of all causes,' so do not expect it to control all types of pneumonia.
Several hundred yuan. In some regions, it is provided free…
Researchers in the Netherlands randomly assigned 84,500 seniors over 65 to two groups for comparison. They use…
Several hundred yuan. In some regions, it is provided free of charge for seniors.
Researchers in the Netherlands randomly assigned 84,500 seniors over 65 to two groups for comparison. They used the 13-valent pneumococcal conjugate vaccine. Its effectiveness against pneumonia caused by strains it targets was 45.6%, with a 95% confidence interval of 21.8–62.5. This figure refers to the specific bacterial strains the vaccine can protect against. For the most dangerous form of pneumococcal disease, the effectiveness was 75.0% (95% CI 41.4–90.8). No protective effect was observed against pneumonia cases caused by any other pathogens.
Bonten MJ, Huijts SM, Bolkenbaas M, et al. (2015). Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. New England Journal of Medicine, 372(12), 1114-1125. https://doi.org/10.1056/NEJMoa1408544
Open source linkThis vaccine only protects against the specific bacterial strains it targets; it does not prevent all types of pneumonia. The 23-valent polysaccharide vaccine commonly used for seniors in China is a different formulation from the 13-valent conjugate vaccine used in this trial, so the effectiveness figures here cannot be directly applied to that vaccine.